For 2026, Grossman said ADMA is forecasting $635 million in revenue and $360 million of EBITDA. He also said the company provided guidance “for the first time” for 2027 of $775 million in revenue and $455 million of EBITDA. Looking longer term, he reiterated the company’s target of $1.1 billion or more in revenue by 2029 and said ADMA anticipates approximately $700 million of EBITDA in 2029, which he noted does not include any potential contribution from its SG01 program.Grossman also provided preliminary, ...

Core Insights - ADMA Biologics, Inc. is focused on developing plasma-derived biologics and has three FDA-approved products, including Asceniv, which is effective against RSV [1] Company Overview - ADMA Biologics, Inc. operates in the biopharmaceutical sector, specializing in products derived from human plasma [1] - The company has a notable product, Asceniv, which is an RSV-enriched immunoglobulin, making it particularly suitable for treating respiratory syncytial virus infections [1]